CRISPR-Cas9 base editing to render CaMKIIδ phosphoresistant improves survival and cardiac function in heart failure

We ablated the autophosphorylation site of CaMKIIδ (T287) using CRISPR-Cas9 adenine base editing technology. Ten-weeks old C57Bl6 wildtype and CaMKIIδ T287A mice were subjected to either sham or severe transverse aortic constriction (sTAC) surgery (WT-Sham, WT-sTAC, T287A-Sham, T287A-sTAC; 3 biological replicates per group). Two weeks after the surgery, hearts were harvested for RNA isolation and subsequent bulk RNA sequencing and gene expression profiling analysis. Comparative gene expression profiling analysis of RNA-seq data for WT-Sham, WT-sTAC, T287A-Sham, and T287A-sTAC.